Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term oral treprostinil extension study in pulmonary arterial hypertension
MOH_2017-04-24_000338Phase 3Recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoint: Long-term safety. Started Oct 2012; status: recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2017-04-24_000338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-24_000338.